Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about ...

or AZ’s Iressa (gefitinib). NICE has ruled that Tagrisso does not meet its end of life criteria, which allows for more flexibility in pricing, as existing drugs are doing enough to prolong ...

Approval based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years In the trial, Tagrisso reduced the risk of disease progression ...

The clinical development of gefitinib (Iressa; AstraZeneca) for treating NSCLC illustrates both the challenges and opportunities in the development of targeted therapies for cancer. In the case of ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

like AstraZeneca's market-leading Tagrisso (osimertinib), AZ’s older Iressa (gefitinib) and Roche’s Tarceva (erlotinib). Over time. most targeted cancer drugs have their efficacy limited by ...

#' @description Argyropoulos and Unruh (2015) published reconstructed IPASS clinical trial data. Despite being reconstructed, this data set retains all of the features shown in references, as well as ...

In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be ...